Table 2.

In solid tumor models, combined treatment with a selective VEGF receptor inhibitor (SU10944) and a selective PDGF receptor inhibitor (Gleevec) recapitulates the antitumor efficacy of SU11248, which inhibits both PDGF receptors and VEGF receptors

Xenograft tumors (days of treatment)Antitumor activity (%)
Treatment similarity
SU10944
Gleevec
SU11248
SU10944 + Gleevec
Effect*PEffect*PEffect*PEffect*P
C6 (d12)760.001720.001920.001970.0010.969
MV4;11 (d15)950.00001No effect1000.00001520.003Not applicable
HT-29 (d18)550.23No effect350.13220.140.886
786-O (d14)900.013400.18460.05400.080.994
WM-266-4 (d29)820.0005350.06370.04270.130.871
H226 (d14)280.111040.01690.001640.00010.997
  • NOTE: Tumors were established as s.c. xenografts. Number of cells implanted per animal: C6, 3 × 106; Colo205, WM-266-4, H226, HT-29, and MV4;11, 5 × 106 (last two plus 50% basement Matrigel matrix); 786-O, 1 × 107 plus 50% basement Matrigel matrix. Once tumors reached the indicated average size, daily treatment with 40 mg/kg of oral SU11248 was initiated. The results of representative experiments are shown here.

  • * Percentage of tumor regression (not bolded) and percentage of growth inhibition (bolded) are shown for representative experiments. P, Student's t test (two-tailed distribution)—in cases when P < 10−5, P = 0.00001 is shown.

  • Overall treatment similarity between SU11248-treated and combination (SU10944 + Gleevec)-treated groups. Calculated as R2, Pearson coefficient between average tumor sizes in the two groups at each measurement throughout the length of the experiment.